CPA/6d treatment of GL261 tumors implanted in adaptive immune deficient scid mice induces major regression, but is sometimes followed by late tumor growth rebound [18], whereas in the fully immune competent B6 mouse model, GL261 tumors are eradicated by a Cd8 T cell-dependent mechanism with acquisition of long term immunity [20]. The gene discussed is CD8A; the disease is neoplasm.